Research graph
References from A comparison of two manufacturing methods in the phase I COBALT study of CD19CAR T for LBCL. Local targets link to admitted publications; unresolved targets remain external evidence.
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
10.1056/nejmoa1708566 · 2017 · External reference
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
10.1056/nejmoa1707447 · 2017 · External reference
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
10.1016/s0140-6736(20)31366-0 · 2020 · External reference
Manufacturing chimeric antigen receptor T cells: issues and challenges
10.1016/j.jcyt.2018.11.009 · 2019 · External reference
Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells
10.1016/j.jcyt.2016.04.003 · 2016 · External reference
Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells
10.1186/s12967-017-1160-5 · 2017 · External reference
Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells
10.1158/2326-6066.cir-17-0405 · 2018 · External reference
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies
10.1182/blood-2015-11-683847 · 2016 · External reference
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells
10.1073/pnas.0503726102 · 2005 · External reference
Towards a commercial process for the manufacture of genetically modified T cells for therapy
10.1038/cgt.2014.78 · 2015 · External reference
Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy
10.1016/j.jcyt.2016.05.009 · 2016 · External reference
Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion
10.1182/blood.2025028790 · 2025 · External reference
A Unique Human B Lymphocyte Antigen Defined by a Monoclonal Antibody
10.1089/hyb.1984.3.305 · 1984 · External reference
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
10.1182/blood-2014-01-552174 · 2014 · External reference
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors
10.1182/blood-2012-05-431718 · 2013 · External reference
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy
10.1182/blood-2014-01-545020 · 2014 · External reference
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
2020 · External reference
Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England
10.1182/blood-2019-124177 · 2019 · External reference
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
2024 · External reference
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
10.1186/s13045-018-0571-y · 2018 · External reference
Accelerating and optimising CAR T-cell manufacture to deliver better patient products
10.1016/s2352-3026(24)00273-4 · 2025 · External reference
Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions
10.1016/j.omtm.2018.11.010 · 2019 · External reference
Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing
10.1016/j.omtm.2021.02.002 · 2021 · External reference
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
10.1172/jci85309 · 2016 · External reference
Equal opportunity CAR T cells
10.1182/blood-2017-04-779983 · 2017 · External reference
Paths to stemness: building the ultimate antitumour T cell
10.1038/nrc3322 · 2012 · External reference
Chimeric antigen receptor T (CAR-T) cells expanded with IL-7/IL-15 mediate superior antitumor effects
10.1007/s13238-019-0643-y · 2019 · External reference
Bispecific LV20.19 CAR T-Cells Expanded in IL-7 and IL-15 Have Greater Polyfunctionality and Polyfunctional Strength Than CAR T-Cells Expanded in IL-2
10.1182/blood-2021-146882 · 2021 · External reference
Cost of decentralized CAR T-cell production in an academic nonprofit setting
10.1002/ijc.33156 · 2020 · External reference
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
10.1182/bloodadvances.2020002394 · 2020 · External reference
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
10.1016/s0140-6736(21)01222-8 · 2021 · External reference
The “cleavage” activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring “2A-like” sequences
10.1099/0022-1317-82-5-1027 · 2001 · External reference
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
10.1182/blood-2016-01-643569 · 2016 · External reference
Revised Response Criteria for Malignant Lymphoma
10.1200/jco.2006.09.2403 · 2007 · External reference
Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy
10.1097/cji.0b013e31823569e2 · 2012 · External reference
